Phlow was proud to welcome senior officials from the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), along with other federal health and preparedness leaders, to our facilities in Richmond and Petersburg,...
2025
Phlow Corp. Achieves Completion of Full-Scale Demonstration of Succinylcholine Chloride Active Pharmaceutical Ingredient (API) Production at its U.S. Metric Ton Facility
Richmond, Virginia, May 14, 2025 — Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced the completion of a successful full-scale demonstration batch of Succinylcholine Chloride at...
Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America
Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System,Ushering in a New Era of Modern Medicine Manufacturing in America Richmond, Virginia — April 22, 2025 — Phlow Corp., a leading pharmaceutical contract development and...
Phlow Corp. Achieves Key Milestone Toward Full Epinephrine Production — Made in America
Validation Completed for a Novel, Cost-Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully Filed Richmond, Virginia, March 17, 2025 -- Phlow Corp., a U.S.-based certified B Corporation on a mission to bring medicines to life...